CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
CAPRICOR THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.65−0.06 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $385.21M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.40 (+6.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CAPRICOR THERAPEUTICS, INC. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$114.90M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$135.16M
TTM Q2 2026
Free cash flow
-$114.90M
TTM Q2 2026
EPS, diluted
-$2.45
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $385.21M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.56
- Dividend yield
- –
- Free cash flow yield
- -29.83%
Fundamentals
- Revenue
- $0
- Net income
- -$129.42M
- EPS, diluted
- -$2.45
- Free cash flow
- -$114.90M
- Book value per share
- $4.25
- Diluted shares
- 58M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$135.16M
Net income
-$129.42M
EPS, diluted
-$2.45
Free cash flow
-$114.90M
Reported periodTrailing twelve months